RLAY
MODERATERelay Therapeutics, Inc.
CIK: 0001812364
Strong Sell
(70% confidence)
Last activity: 2 weeks ago
Financial Metrics
As of Sep 30, 2025 (10-Q)
Revenue $25.55M
Net Income -$221.59M
Insider Roster (4 total, 4 active)
| Insider | Buys | Sells | Net Value | Holdings |
|---|---|---|---|---|
| Patel Sanjiv President and CEO | 0 | 1 | -$338K | 661,041 shares $5.17M |
| Bergstrom Donald A President, R&D | 0 | 2 | -$167K | 420,047 shares $3.55M |
| Catinazzo Thomas Chief Financial Officer | 0 | 2 | -$120K | 249,301 shares $2.11M |
| Rahmer Peter See remarks | 0 | 2 | -$100K | 276,610 shares $2.34M |
Recent Transactions
SELL Bergstrom Donald A (President, R&D)
2,686 shares @ $8.45
$23K
Jan 28, 2026
Conviction: |
View SEC Filing →
SELL Catinazzo Thomas (Chief Financial Officer)
1,695 shares @ $8.45
$14K
Jan 28, 2026
Conviction: |
View SEC Filing →
SELL Rahmer Peter (See remarks)
1,354 shares @ $8.45
$11K
Jan 28, 2026
Conviction: |
View SEC Filing →
SELL Bergstrom Donald A (President, R&D)
18,895 shares @ $7.62
$144K
Jan 27, 2026
Conviction: |
View SEC Filing →
SELL Catinazzo Thomas (Chief Financial Officer)
13,820 shares @ $7.62
$105K
Jan 27, 2026
Conviction: |
View SEC Filing →
SELL Rahmer Peter (See remarks)
11,684 shares @ $7.62
$89K
Jan 27, 2026
Conviction: |
View SEC Filing →
SELL Patel Sanjiv (President and CEO)
43,168 shares @ $7.82
$338K
Jan 6, 2026
Conviction: |
View SEC Filing →
⚠️ Important Disclaimer
• This is AI-generated analysis for educational purposes only, not financial advice.
• Insider trading data is derived from SEC Form 4 filings and may contain errors.
• Always conduct your own research and consult qualified financial advisors before making investment decisions.